Flexion Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. Co.'s product, ZILRETTA®, is an injection indicated for the management of OA knee pain. Co. has two product candidates focused on the treatment of musculoskeletal conditions: FX201 and FX301. FX201, is a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist. FX301, is a NaV1.7 inhibitor formulated for extended release in a thermosensitive hydrogel. The FLXN average annual return since 2014 is shown above.
The Average Annual Return on the FLXN average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FLXN average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FLXN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|